221 related articles for article (PubMed ID: 22337941)
1. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.
Lazarus MN; Turner-Stokes T; Chavele KM; Isenberg DA; Ehrenstein MR
Rheumatology (Oxford); 2012 Jul; 51(7):1208-15. PubMed ID: 22337941
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
Carter LM; Isenberg DA; Ehrenstein MR
Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
[TBL] [Abstract][Full Text] [Related]
3. B cell biomarkers of rituximab responses in systemic lupus erythematosus.
Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
Arthritis Rheum; 2011 Oct; 63(10):3038-47. PubMed ID: 21618204
[TBL] [Abstract][Full Text] [Related]
4. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
Clin Immunol; 2007 Jan; 122(1):62-74. PubMed ID: 17046329
[TBL] [Abstract][Full Text] [Related]
5. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.
Watson L; Beresford MW; Maynes C; Pilkington C; Marks SD; Glackin Y; Tullus K
Lupus; 2015 Jan; 24(1):10-7. PubMed ID: 25117653
[TBL] [Abstract][Full Text] [Related]
6. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE).
Spronk PE; Horst G; Van Der Gun BT; Limburg PC; Kallenberg CG
Clin Exp Immunol; 1996 Jun; 104(3):446-53. PubMed ID: 9099929
[TBL] [Abstract][Full Text] [Related]
7. Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins.
Reddy V; Martinez L; Isenberg DA; Leandro MJ; Cambridge G
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):857-866. PubMed ID: 27428176
[TBL] [Abstract][Full Text] [Related]
8. Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
Kneitz C; Wilhelm M; Tony HP
Immunobiology; 2002 Dec; 206(5):519-27. PubMed ID: 12607727
[TBL] [Abstract][Full Text] [Related]
9. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
10. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities.
Chauhan SK; Rai R; Singh VV; Rai M; Rai G
Immunol Lett; 2015 Dec; 168(2):254-9. PubMed ID: 26434792
[TBL] [Abstract][Full Text] [Related]
11. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
Cambridge G; Leandro MJ; Teodorescu M; Manson J; Rahman A; Isenberg DA; Edwards JC
Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
[TBL] [Abstract][Full Text] [Related]
12. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.
Bootsma H; Spronk PE; Ter Borg EJ; Hummel EJ; de Boer G; Limburg PC; Kallenberg CG
Ann Rheum Dis; 1997 Nov; 56(11):661-6. PubMed ID: 9462168
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells.
Zhang J; Jacobi AM; Wang T; Diamond B
Mol Med; 2008; 14(11-12):675-81. PubMed ID: 18677426
[TBL] [Abstract][Full Text] [Related]
16. Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody.
Saigal R; Goyal LK; Agrawal A; Mehta A; Mittal P; Yadav RN; Meena PD; Wadhvani D
J Assoc Physicians India; 2013 Jun; 61(6):372-7. PubMed ID: 24640201
[TBL] [Abstract][Full Text] [Related]
17. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Jacobi AM; Huang W; Wang T; Freimuth W; Sanz I; Furie R; Mackay M; Aranow C; Diamond B; Davidson A
Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.
Wirestam L; Schierbeck H; Skogh T; Gunnarsson I; Ottosson L; Erlandsson-Harris H; Wetterö J; Sjöwall C
Arthritis Res Ther; 2015 Nov; 17():338. PubMed ID: 26596890
[TBL] [Abstract][Full Text] [Related]
20. Rituximab therapy for juvenile-onset systemic lupus erythematosus.
Nwobi O; Abitbol CL; Chandar J; Seeherunvong W; Zilleruelo G
Pediatr Nephrol; 2008 Mar; 23(3):413-9. PubMed ID: 18097688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
